A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...

Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...

Kennedy Jr., who has been tapped by Trump to lead the HHS, has been critical of Ozempic and other weight loss drugs.

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

The two drugs are metformin, one of the most widely used diabetes medications, and the GLP-1 class of medications that ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...